PEG Polymer Hydrating Layer for Vaginal Mucosa
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vaginal atrophy, such as hormone replacement therapy and plant-based substances, have systemic side effects due to non-local action, and existing polymers for barrier protection may not effectively address the specific hydration needs of the vaginal mucosa.
Innovation Solution
Pharmaceutical compositions in solid form using PEGs with a molecular weight of 3000 or more, combined with surfactants, acidifiers, and disintegrating agents, to create a localized hydrating effect that improves vaginal mucosa trophism without systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone replacement therapy or plant-based substances are used to treat vaginal atrophy, then the therapeutic effect on vaginal mucosa is improved, but systemic side effects occur due to non-local action
Solution Approach 1:
The patent applies local quality by using a polymer composition that acts exclusively at the local vaginal level. The polymer matrix with controlled porosity (2-20 micrometers) enables localized drug delivery to the vaginal mucosa, ensuring the therapeutic agent acts only where needed without systemic distribution. This resolves the contradiction by maintaining therapeutic efficacy while eliminating systemic side effects through spatially restricted action.
Solution Approach 2:
The patent uses a polymer intermediary (crosslinked polyacrylic acid or polyvinyl alcohol) as a delivery vehicle. This polymer matrix absorbs water to form a gel that locally releases the therapeutic agent at the vaginal site. The polymer acts as an intermediary carrier that transports the active ingredient locally without allowing systemic absorption, thus achieving therapeutic effect while avoiding systemic side effects.
2Object-affected harmful factors
If barrier polymers are used to protect vaginal mucosa, then protection against pathogenic micro-organisms is improved, but the specific hydration needs of vaginal mucosa are not effectively addressed
Solution Approach 1:
The patent merges two functions into a single polymer composition: (1) barrier protection against pathogenic micro-organisms through the polymer matrix structure, and (2) hydration of vaginal mucosa through water-absorbing capability of the polymer. The crosslinked polymer network simultaneously provides mechanical barrier function and osmotic hydration, resolving the contradiction by combining protective and hydrating functions in one system.
Solution Approach 2:
The patent uses composite materials by combining water-absorbing polymers (polyacrylic acid or polyvinyl alcohol) with therapeutic agents and forming a crosslinked gel matrix. This composite structure integrates the barrier properties of the polymer network with the hydrating capability of the hydrophilic polymer chains, achieving both protection and hydration simultaneously.
3Reliability
If polymers with high water absorption are used, then hydration of vaginal mucosa is improved, but barrier protection function is reduced
Solution Approach 1:
The patent applies parameter changes by controlling the porosity of the polymer matrix within a specific range (2-20 micrometers) and adjusting the crosslinking degree of the polymer. These parameter optimizations enable the polymer to simultaneously achieve high water absorption for hydration while maintaining sufficient structural integrity for barrier protection. The specific porosity range allows water penetration for hydration while preventing pathogenic micro-organism invasion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide a stable improvement in vaginal mucosa trophism by forming a hydrating layer, maintaining optimal pH, and inhibiting pathogenic microbes, as demonstrated by significant increases in vaginal secretions and pH levels in clinical trials.
Implementation Method 1
They exert a considerable osmotic attraction on water... the observed effect on trophism takes place unexpectedly, depending on the physical properties... their use would cause water attraction useful for normal basal activities of the target site
Implementation Method 2
surfactants can be added, i.e. substances that reduce the surface tension of the aqueous medium on the surfaces with which they come into contact, facilitating and standardising the wetting of said surfaces and therefore accelerating the penetration of the water required for hydration
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to the use of pharmaceutical compositions in solid form containing PEGs of a grade exceeding 3000 for the treatment or prevention of vaginal atrophy.